The VanMoof S4 and X4 E-Bikes Reflect 13 Years of Innovation
Including rider-favorite features for an upgraded experience.
The VanMoof S4 and X4 e-bikes will launch in “Evergreen,” “Sunbeam Yellow,” “Purple Fog,” and “Foam Green” colorways, available on May 9 for $2,498 USD
Including rider-favorite features for an upgraded experience.
The VanMoof S4 and X4 e-bikes will launch in “Evergreen,” “Sunbeam Yellow,” “Purple Fog,” and “Foam Green” colorways, available on May 9 for $2,498 USD
苏联二战红星勋章，银质珐琅，1个角珐琅有脱皮号段：“1506886”，属于杰尼索夫同志，在袭击绍尔诺克镇期间，近距离击杀20人，，摧毁了2个机枪射击点，在房子的屋顶上，他注意到敌军机枪火力点，没有迟疑，摧毁了2处机枪火力点，俘虏了1处，包含部分电子档案。
USSR Order “Red Star” #1506886 with research.
Denisov Vasiliy Fedoseevich (Денисов Василий Федосеевич) – sergeant, male, birth in 1918, member of CPSU since 1945, lower education, Russian, served in Red Army from August, 1941 to May 1946.
Was awarded by:
Order “Red Star” #1506886
Medal “for Victory over Germany”
Order “Patriotic War” 1st Class #283424
Order “Red Star” #1506886 awarded for:
Denisov Vasiliy Fedoseevich – sergeant, commander of squad of 12 rifle company of 777 rifle Sevastopol regiment of 227 rifle Red Banner Ternopol division.
Participant of combats, during assault of town Szolnok, showing bravery and heroism, together with this squad, sneaked into enemy’s rear and caused panic and from short-range killed more than 20 Germans, destroyed 2 machine-gun fire points.
On house’s roof he noticed machine-gun with 4 German’s, didn’t confused, killed 2 and captured other and destroyed machine-gun by grenade.
November 9, 1944 Commander of 777 rifle regiment
Lieutenant-colonel
Combats in Hungary.
USSR Order “Red Star” #1506886 with research.
Denisov Vasiliy Fedoseevich (Денисов Василий Федосеевич) – sergeant, male, birth in 1918, member of CPSU since 1945, lower education, Russian, served in Red Army from August, 1941 to May 1946.
Was awarded by:
Order “Red Star” #1506886
Medal “for Victory over Germany”
Order “Patriotic War” 1st Class #283424
Order “Red Star” #1506886 awarded for:
Denisov Vasiliy Fedoseevich – sergeant, commander of squad of 12 rifle company of 777 rifle Sevastopol regiment of 227 rifle Red Banner Ternopol division.
Participant of combats, during assault of town Szolnok, showing bravery and heroism, together with this squad, sneaked into enemy’s rear and caused panic and from short-range killed more than 20 Germans, destroyed 2 machine-gun fire points.
On house’s roof he noticed machine-gun with 4 German’s, didn’t confused, killed 2 and captured other and destroyed machine-gun by grenade.
November 9, 1944 Commander of 777 rifle regiment
Lieutenant-colonel
Combats in Hungary.
#国际创新药闻# 眼科新药在美国申报上市，远大医药拥有中国独家权益
5月8日，远大医药发布新闻稿称，其眼科领域合作伙伴台新药股份有限公司公布其用于抗炎镇痛的激素纳米混悬滴眼液GPN00833（APP13007）已向美国FDA递交了新药上市申请（NDA）。根据远大医药新闻稿，该公司拥有GPN00833在中国大陆、香港和澳门地区的独家开发和商业化权利，此次该产品的重大海外进展将会进一步为中国的注册工作提供支持。
GPN00833为一种强效皮质类固醇丙酸氯倍他索（0.05%）的新型水性纳米混悬滴眼液，其独特的纳米制剂工艺有效解决了激素产品低水溶性导致的生物利用度低及安全性风险，增强了药物在眼部组织的渗透性，同时患者对产品的使用舒适度良好。
此前，GPN00833在美国开展的2期临床试验（CPN-201）及两项3期临床试验（CPN301及CPN-302）均达到了临床终点。对三项临床研究综合统计分析的结果显示：1）安全性方面，治疗组和对照组数据相当，受试者对该产品耐受性良好；2）抗炎方面，持续给药14天后，治疗组与对照组受试者前方细胞数量（炎症指标）为零的比例是58.2% vs 17.3%；3）镇痛方面，治疗组与对照组的受试者在第4天即反应疼痛指数为零的比例为81.4% vs 47.4%；4）药效持续性方面，治疗组与对照组受试者自第4天到第15天维持疼痛指数为零之比例为71.6% vs 27.7%。综上分析显示，GPN00833在针对白内障术后抗炎镇痛方面疗效显著优于对照组，且安全性良好。
在中国，GPN00833已于今年4月获批开展3期临床研究。这是一项多中心、随机、双盲、安慰剂对照的3期临床研究，拟入组252例接受白内障手术的患者，旨在评估GPN00833用于治疗白内障手术后炎症和疼痛的有效性和安全性。
参考资料：
[1]远大医药全球创新眼科药物GPN00833向美国FDA递交新药上市申请. Retrieved May 8, 2023. From https://t.cn/A6NEov8L
[2]远大医药全球创新眼科药物GPN00833的中国III期临床试验申请获国家药监局默示许可. Retrieved Apr 23, 2023. From https://t.cn/A6NEov82
来源：医药观澜
如涉及版权，请联系删除
5月8日，远大医药发布新闻稿称，其眼科领域合作伙伴台新药股份有限公司公布其用于抗炎镇痛的激素纳米混悬滴眼液GPN00833（APP13007）已向美国FDA递交了新药上市申请（NDA）。根据远大医药新闻稿，该公司拥有GPN00833在中国大陆、香港和澳门地区的独家开发和商业化权利，此次该产品的重大海外进展将会进一步为中国的注册工作提供支持。
GPN00833为一种强效皮质类固醇丙酸氯倍他索（0.05%）的新型水性纳米混悬滴眼液，其独特的纳米制剂工艺有效解决了激素产品低水溶性导致的生物利用度低及安全性风险，增强了药物在眼部组织的渗透性，同时患者对产品的使用舒适度良好。
此前，GPN00833在美国开展的2期临床试验（CPN-201）及两项3期临床试验（CPN301及CPN-302）均达到了临床终点。对三项临床研究综合统计分析的结果显示：1）安全性方面，治疗组和对照组数据相当，受试者对该产品耐受性良好；2）抗炎方面，持续给药14天后，治疗组与对照组受试者前方细胞数量（炎症指标）为零的比例是58.2% vs 17.3%；3）镇痛方面，治疗组与对照组的受试者在第4天即反应疼痛指数为零的比例为81.4% vs 47.4%；4）药效持续性方面，治疗组与对照组受试者自第4天到第15天维持疼痛指数为零之比例为71.6% vs 27.7%。综上分析显示，GPN00833在针对白内障术后抗炎镇痛方面疗效显著优于对照组，且安全性良好。
在中国，GPN00833已于今年4月获批开展3期临床研究。这是一项多中心、随机、双盲、安慰剂对照的3期临床研究，拟入组252例接受白内障手术的患者，旨在评估GPN00833用于治疗白内障手术后炎症和疼痛的有效性和安全性。
参考资料：
[1]远大医药全球创新眼科药物GPN00833向美国FDA递交新药上市申请. Retrieved May 8, 2023. From https://t.cn/A6NEov8L
[2]远大医药全球创新眼科药物GPN00833的中国III期临床试验申请获国家药监局默示许可. Retrieved Apr 23, 2023. From https://t.cn/A6NEov82
来源：医药观澜
如涉及版权，请联系删除
✋热门推荐